MARKET

EWTX

EWTX

Edgewise Therapeutics, Inc.
NASDAQ
23.75
-1.07
-4.29%
After Hours: 23.36 -0.39 -1.64% 17:26 01/02 EST
OPEN
25.08
PREV CLOSE
24.82
HIGH
25.08
LOW
23.66
VOLUME
1.00M
TURNOVER
--
52 WEEK HIGH
30.48
52 WEEK LOW
10.60
MARKET CAP
2.51B
P/E (TTM)
-15.0593
1D
5D
1M
3M
1Y
5Y
1D
Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst
Seeking Alpha · 12/29/2025 19:55
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Edgewise Therapeutics (EWTX)
TipRanks · 12/29/2025 13:20
Weekly Report: what happened at EWTX last week (1222-1226)?
Weekly Report · 12/29/2025 09:36
Edgewise Therapeutics: Advancing EDG-7500 in Hypertrophic Cardiomyopathy Underpins Buy Rating and Future Value Catalysts
TipRanks · 12/26/2025 13:25
Why Edgewise Therapeutics Stock Rocked the Market Today
The Motley Fool · 12/24/2025 23:20
Gold Edges Lower; Omeros Shares Jump
Benzinga · 12/24/2025 17:21
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating
TipRanks · 12/24/2025 16:45
H.C. Wainwright says Edgewise data reinforces EDG-7500 potential differentiation
TipRanks · 12/24/2025 16:40
More
About EWTX
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

Webull offers Edgewise Therapeutics Inc stock information, including NASDAQ: EWTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EWTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EWTX stock methods without spending real money on the virtual paper trading platform.